Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Odds of approval now?
View:
Post by Tson99 on Nov 25, 2015 8:44am

Odds of approval now?

Anyone with a WAG on what the odds of approval are now?
Comment by vega509 on Nov 25, 2015 10:50am
th eonly sure thing with TST now is a steadily declining share price until management announces its intentions going forward. at 23¢ TST would be a take over target if there was any confidence in managements plan. their silence is only making investors and partners more uncertain as to its value. the possible reverse split will only make this situation worse. hang on, we could be sub 20¢ ...more  
Comment by DamnYankees on Nov 25, 2015 10:55am
vega. The only person close to the story who has said anything, mentioned the potential to trade at "cash value". It could go to a dime. What bearing does that have on Step 2 with the FDA? None.
Comment by ragingbull1327 on Nov 25, 2015 10:58am
That would be amazing if they go to a dime.  I'll quadruple up....
Comment by ragingbull1327 on Nov 25, 2015 10:57am
A takeover target at 0.23 eh?    Someone will WANT it for whatever reason and you think the people who own a billion dollar house are going to sell something that other people want for cheap?    How do you continue to play out these crazy scenarios in your head?  
Comment by ragingbull1327 on Nov 25, 2015 11:00am
I've already said it before, and you're missing the point.    IT'S NOT US WHO LOSE, IF THE TREATMENT DOESNT GET APPROVAL.    It's the doctors and the patients who lose.   How the hell hard is THIS to figure out?    What's their alternative?   Pure chit
Comment by ragingbull1327 on Nov 25, 2015 11:01am
Actually, Valstar is so bad that it's embarrassing that's all there was for so long.    So things can't get worse.  They can just "stay bad".   lol.   Over educated in science.   Under educated in common sense 
Comment by DamnYankees on Nov 25, 2015 11:16am
Valstar? I think those involved have concrete opinions on Valstar. As I have said several times, over several months, if Telesta is unable to bring MCNA to market, Endo will. It may be on behalf of Telesta or it may be as a post banruptcy, former Telesta property, but they will bring it to market! In my humblest of opinions.
Comment by thathurt on Nov 25, 2015 11:18am
tson to me the answer to your question is three areas: a) what does the science of MCNA suggest: IMO net-net safety and effcicacy approvable as 2nd line b) can TST execs communicate the science of MCNA sufficiently well for approval; well AdCom result would suggest to me they could very well be "in-over-their heads" as i suspect they, within their level of competence, put their best ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities